Trial Profile
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Oct 2023 Status changed from active, no longer recruiting to completed.
- 01 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 01 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.